Among these, tazemetostat/EPZ-6438 (Epizyme, Inc., Cambridge, MA, USA) has been recently approved by FDA for patients with advanced epithelioid sarcoma [18] and has also entered into clinical trials for diffuse large B-cell lymphoma [19], follicular lymphoma [20], and relapsed or refractory MPM with BRCA1 associated protein 1 (BAP1) inactivation [21,22]. This evidence concerns the gene BAP1 and diffuse large B-cell lymphoma.